In the pooled cohort, 283 patients with advanced NSCLC and PD-L1 expression ≥50% were treated with cemiplimab monotherapy, and 312 patients with advanced NSCLC and no EGFR, ALK, or ROS1 genomic aberrations were treated with cemiplimab plus chemotherapy (9, 10). Here, CD274 is linked to non-small cell lung carcinoma.